Ultragenyx Pharmaceutical Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 741.98, 983.21, 1235.81, 1673.59, 2307.67 ], "ebit_estimate": [ -442.71, -76.38, 109.29, 407.53, 753.76 ], "ebitda_estimate": [ -409.9, -57.74, 88.56, -68.29, 90.56 ], "net_income_estimate": [ -471.14, -86.71, 66.53, 335.63, 596.34 ], "per_share_eps_estimate": [ -4.25, -1.18, 0.51, 3.38, 4.5 ], "eps_nri_estimate": [ -4.63, -0.87, 0.5, 3.08, 6.14 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 1.03, 2.59, 2.61, null, null ], "pretax_income_estimate": [ -469.67, -107.06, 39.33, 350.08, 696.63 ], "operating_cash_flow_per_share_estimate": [ -3.51, 0.37, 2.75, null, null ], "roa_estimate": [ -36.9, -12.3, 12.4, null, null ], "roe_estimate": [ 72.5, 41.4, -82.24, null, null ], "gross_margin_estimate": [ 81.4, 83, 83, 80, 80 ], "operating_cash_flow_estimate": [ -352.6, 37.22, 276.65, null, null ], "pettm_estimate": [ 0, 0, 65.8, 9.99, 7.51 ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "23.43", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 23.43, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 181.72, 183.86, 239.03, 198.58, 238.6, 257.61, 332.9 ], "ebit_estimate": [ -113.34, -103.56, -61.59, -81.62, -33.95, -24.88, 63.85 ], "ebitda_estimate": [ -92.92, -81.53, -73.04, -96.42, -63.9, -63.28, -50.63 ], "net_income_estimate": [ -124.18, -111.39, -70.43, -87.61, -58.09, -38.61, 50.42 ], "per_share_eps_estimate": [ -1.26, -1.12, -0.73, -0.8, -0.53, -0.34, 0.23 ], "eps_nri_estimate": [ -1.23, -1.1, -0.71, -0.8, -0.53, -0.34, 0.45 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ -0.77, -1.78, -2.31, null, null, null, null ], "pretax_income_estimate": [ -123.54, -112.36, -70.13, -87.55, -58.09, -38.61, 50.42 ], "operating_cash_flow_per_share_estimate": [ 1.06, 4.09, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null ], "gross_margin_estimate": [ 80, 80, 80, 81, 81, 81, 81 ], "operating_cash_flow_estimate": [ 106.64, 411.45, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "23.43", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 23.43, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }